Perpetual Ltd Reduces Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Perpetual Ltd has reduced its stake in Jazz Pharmaceuticals PLC by 6.8%, now holding approximately 887,583 shares valued at around $94.19 million.
• A significant portion of Jazz Pharmaceuticals' stock, about 89.14%, is owned by institutional investors, indicating strong institutional interest in the company.
• Recent analyst ratings for Jazz Pharmaceuticals include raised price targets, with some analysts giving a buy rating and a consensus target of $178.67.

Perpetual Ltd reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 6.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 887,583 shares of the specialty pharmaceutical company's stock after selling 64,589 shares during the period. Jazz Pharmaceuticals makes up approximately 1.1% of Perpetual Ltd's holdings, making the stock its 25th largest holding. Perpetual Ltd owned approximately 1.47% of Jazz Pharmaceuticals worth $94,190,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of JAZZ. Wealth Enhancement Advisory Services LLC raised its stake in shares of Jazz Pharmaceuticals by 25.3% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 5,429 shares of the specialty pharmaceutical company's stock valued at $594,000 after acquiring an additional 1,095 shares during the last quarter. Swedbank AB increased its holdings in Jazz Pharmaceuticals by 10.0% in the first quarter. Swedbank AB now owns 1,102,143 shares of the specialty pharmaceutical company's stock valued at $136,831,000 after purchasing an additional 100,211 shares during the last quarter. Voya Investment Management LLC lifted its stake in Jazz Pharmaceuticals by 67.1% in the first quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company's stock valued at $6,996,000 after buying an additional 22,628 shares during the period. Inspire Investing LLC acquired a new position in Jazz Pharmaceuticals in the first quarter valued at about $689,000. Finally, Strs Ohio acquired a new position in Jazz Pharmaceuticals in the first quarter valued at about $2,042,000. 89.14% of the stock is currently owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director owned 429,973 shares of the company's stock, valued at $55,303,127.26. This represents a 1.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on JAZZ shares. Truist Financial boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a report on Thursday, August 28th. The Goldman Sachs Group boosted their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a report on Friday, August 29th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price for the company. Finally, Royal Bank Of Canada increased their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research note on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $178.67.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $1.89 during midday trading on Monday, hitting $130.19. The company's stock had a trading volume of 802,328 shares, compared to its average volume of 934,854. The stock has a fifty day moving average price of $120.39 and a 200 day moving average price of $115.94. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $7.90 billion, a price-to-earnings ratio of -19.34, a P/E/G ratio of 7.96 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business's revenue was up 2.1% on a year-over-year basis. During the same period last year, the company posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.